Hello, everyone, and welcome to another working week. We hope the weekend respite was refreshing and relaxing because, once again, we have returned to that oh-so-familiar routine of meetings, deadlines, and the like. But you knew this would happen. How could it not? The world keeps spinning, no matter how much we desire to hit the pause button. So fire up the coffee kettle on this frosty morning and join us for a cup of stimulation as we dig in for another busy day. Hope your own journey goes smoothly and, as always, keep us in mind when something fascinating occurs …

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will cut the price of their Praluent cholesterol drug by 60 percent to $5,850 a year, matching an unprecedented move that Amgen (AMGN) made last year with its own Repatha treatment, STAT writes. The companies, whose injectable drugs both had a list price of $14,000 per patient per year and were once expected to generate more than $1 billion in annual sales, have struggled as insurers and pharmacy benefit managers have made it difficult for patients to get the medications.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy